▶ 調査レポート

世界の咳止め薬市場(~2027):疾患種類別、薬物種類別、年齢層別、剤形別、流通チャネル別、地域別

• 英文タイトル:Cough Suppressant Drugs Market Research Report by Disease Type, Drug Type, Age Group, Dosage Form, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。世界の咳止め薬市場(~2027):疾患種類別、薬物種類別、年齢層別、剤形別、流通チャネル別、地域別 / Cough Suppressant Drugs Market Research Report by Disease Type, Drug Type, Age Group, Dosage Form, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2302F0212資料のイメージです。• レポートコード:MRC2302F0212
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、255ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥692,860 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,392,860 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、2021年の1,818.60百万ドルであった世界の咳止め薬市場規模が、2022年に1,897.79百万ドルへ達し、2027年までに年平均4.53%成長し、2,372.53百万ドルへ拡大すると見込んでいます。本書は、咳止め薬の世界市場を対象に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患種類別(乾性咳嗽、湿性咳嗽)分析、薬物種類別(ベンゾナテート、ブタミラート、コデイン、デキストロメトルファン、その他)分析、年齢層別(成人、小児)分析、剤形別(シロップ、錠剤)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの項目について調査・分析を行っています。また、市場調査の対象企業には、Acella Pharmaceuticals, LLC、Amneal Pharmaceuticals, Inc.、Aurobindo Pharma Limited、Aytu BioScience, Inc.などが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の咳止め薬市場規模:疾患種類別
- 乾性咳嗽における市場規模
- 湿性咳嗽における市場規模
・世界の咳止め薬市場規模:薬物種類別
- ベンゾナテートの市場規模
- ブタミラートの市場規模
- コデインの市場規模
- デキストロメトルファンの市場規模
- その他咳止め薬の市場規模
・世界の咳止め薬市場規模:年齢層別
- 成人における市場規模
- 小児における市場規模
・世界の咳止め薬市場規模:剤形別
- シロップ型咳止め薬の市場規模
- 錠剤型咳止め薬の市場規模
・世界の咳止め薬市場規模:地域別
- 南北アメリカの咳止め薬市場規模
アメリカの咳止め薬市場規模
カナダの咳止め薬市場規模
ブラジルの咳止め薬市場規模
...
- アジア太平洋の咳止め薬市場規模
日本の咳止め薬市場規模
中国の咳止め薬市場規模
インドの咳止め薬市場規模
韓国の咳止め薬市場規模
台湾の咳止め薬市場規模
...
- ヨーロッパ/中東/アフリカの咳止め薬市場規模
イギリスの咳止め薬市場規模
ドイツの咳止め薬市場規模
フランスの咳止め薬市場規模
ロシアの咳止め薬市場規模
...
- その他地域の咳止め薬市場規模
・競争状況
・企業情報

The Global Cough Suppressant Drugs Market size was estimated at USD 1,818.60 million in 2021 and expected to reach USD 1,897.79 million in 2022, and is projected to grow at a CAGR 4.53% to reach USD 2,372.53 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Cough Suppressant Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the market was studied across Dry Cough and Wet Cough.

Based on Drug Type, the market was studied across Benzonatate, Butamirate, Codeine, Dextromethorphan, Noscapine, and Pholcodine.

Based on Age Group, the market was studied across Adult and Pediatric.

Based on Dosage Form, the market was studied across Syrup and Tablet.

Based on Distribution Channel, the market was studied across Hospital, Online Pharmacy, and Retail Drug Store.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cough Suppressant Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cough Suppressant Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cough Suppressant Drugs Market, including Acella Pharmaceuticals, LLC, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Aytu BioScience, Inc., GlaxoSmithKline plc, Mayne Pharma, Inc., Pfizer Inc., Taro Pharmaceutical Industries, Tris Pharma, Inc., and Vernalis plc.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Cough Suppressant Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cough Suppressant Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cough Suppressant Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cough Suppressant Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cough Suppressant Drugs Market?
6. What is the market share of the leading vendors in the Global Cough Suppressant Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cough Suppressant Drugs Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the cases of chronic cough
5.1.1.2. Growing demand for cough suppressant drugs by the consumers
5.1.1.3. Surge in demand from the medical industry
5.1.2. Restraints
5.1.2.1. Side effects associated with the use of cough suppressant drugs
5.1.3. Opportunities
5.1.3.1. Rise in the number of product launches
5.1.3.2. Ongoing research activities in the healthcare sector
5.1.4. Challenges
5.1.4.1. Huge cost associated with treatment and shortage of skilled labor
5.2. Cumulative Impact of COVID-19

6. Cough Suppressant Drugs Market, by Disease Type
6.1. Introduction
6.2. Dry Cough
6.3. Wet Cough

7. Cough Suppressant Drugs Market, by Drug Type
7.1. Introduction
7.2. Benzonatate
7.3. Butamirate
7.4. Codeine
7.5. Dextromethorphan
7.6. Noscapine
7.7. Pholcodine

8. Cough Suppressant Drugs Market, by Age Group
8.1. Introduction
8.2. Adult
8.3. Pediatric

9. Cough Suppressant Drugs Market, by Dosage Form
9.1. Introduction
9.2. Syrup
9.3. Tablet

10. Cough Suppressant Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital
10.3. Online Pharmacy
10.4. Retail Drug Store

11. Americas Cough Suppressant Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Cough Suppressant Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Cough Suppressant Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles
15.1. Acella Pharmaceuticals, LLC
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Amneal Pharmaceuticals, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Aurobindo Pharma Limited
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Aytu BioScience, Inc.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. GlaxoSmithKline plc
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Mayne Pharma, Inc.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Pfizer Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Taro Pharmaceutical Industries
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Tris Pharma, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Vernalis plc
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services

16. Appendix
16.1. Discussion Guide
16.2. License & Pricing